Navigation Links
Biodel Reports Third Quarter Fiscal Year 2011 Financial Results
Date:8/4/2011

product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles.  For further information regarding Biodel, please visit the company's website at www.biodel.com.  

Safe-Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candidates, including the potential timing, design and outcomes of clinical trials; and the company's ability to develop and commercialize product candidates.  Forward-looking statements represent our management's judgment regarding future events.  All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements.  The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to respond to the complete response letter regarding our new drug application for Linjeta™ in a timely manner and the possibility that information we provide in response to the letter may not be accepted by the FDA;
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
2. Biodel to Raise $30 Million Through Registered Direct Offering
3. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
4. Biodel Announces Name Change for Lead Product Candidate
5. Dyadic International Reports 2011 Second Quarter Financial Results
6. Vermillion Reports Results for the Second Quarter 2011
7. ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports
8. Dendreon Reports Second Quarter 2011 Financial Results
9. Cambrex Reports Second Quarter of 2011 Results
10. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
11. Gen-Probe Reports Financial Results for the Second Quarter of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , September 23, 2014 ... from Imperial Innovations, Cambridge Innovation Capital and Johnson ... clinical cancer genomics company focused on harnessing the ... improve cancer testing and treatment, today announced it ... by Imperial Innovations and including Cambridge Innovation Capital ...
(Date:9/22/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/94pdq3/global ... "Global Biotechnology Reagents Market 2014-2018" report to ... Biotechnology reagents are chemical compounds or substances ... and examine another substance to provide a test ... prepare, collect, and examine specimens from the human ...
(Date:9/22/2014)... The University of Manchester have generated a new star-shaped molecule ... of its kind ever created. , Known as ... create one for over a quarter of a century and ... Chemistry . , Consisting of two molecular triangles, entwined ... interlocked molecules are tiny each triangle is 114 atoms ...
(Date:9/22/2014)... This is a professional and in-depth study on ... in Global and China. The report provides a basic ... chain structure. Global market analysis and Chinese domestic market ... trends and competitive landscape of the market. A comparison ... , The report also focuses on development policies and ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 3
... BEIJING , July 6 /PRNewswire-Asia-FirstCall/ ... the development, assembly, marketing and,sale of medical devices and homecare medical products ... sell 10,000 oxygen-chip units to,Beijing C&D Co., Ltd. for RMB11 million ... , , ...
... XIANYANG, China , July ... ) ("Biostar" or "the Company"), the,Xianyang-based manufacturer of a ... other pharmaceutical products, today,announced that Mr. Deyin "Bill" ... July 1, 2010 . Mr. Chen replaces Ms. ...
... ROCKVILLE, Md. , July 6 Novavax, Inc. ... Gregory Glenn , M.D., as the company,s Chief Scientific Officer ... and Chief Executive Officer of Novavax.  Previously, Dr. Glenn was ... an associate in international health at Johns Hopkins University,s ...
Cached Biology Technology:Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 2Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 3Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 4Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer 2Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 2Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 4
(Date:9/21/2014)... of children with autism are significantly less likely to ... than the mothers of children who are developing normally, ... Institute has found. , Low iron intake was associated ... child if the mother was 35 or older at ... suffered from metabolic conditions such as obesity hypertension or ...
(Date:9/21/2014)... immune T cells may have the ability to trigger ... study led by King,s College London. Although their immune ... may still be able to mount a strong immune ... Nature Medicine . , Our immune system is made ... neutrophils which play an important role in the frontline ...
(Date:9/19/2014)... A University of Oklahoma biology professor will study the ... analysis that could eventually benefit people,s health. The ... manage the energy required to produce the signals used ... generate electric signals at a rate of 500-600 discharges ... required for the electric fish are extreme, but necessary ...
Breaking Biology News(10 mins):Mothers of children with autism less likely to have taken iron supplements 2Immune system of newborn babies is stronger than previously thought 2
... Biological Sciences Research Council (BBSRC)-led Integrated Biorefining Research and ... which could be used to make biofuel production more ... Issue of the American Chemical Society journal Biochemistry ... the Universities of Warwick and British Columbia, could make ...
... Carolina State University have developed a new technique ... a computer,s ability to build computer models of ... algorithms used to build models of biological systems ... can account for uncertainty and biological variation. This ...
... Institute has won a four-year, $1.9 million grant from ... parasite that causes malaria, laying the groundwork to develop ... "Many antimalarial drugs alleviate symptoms, but do ... malaria parasites are able to persist asymptomatically in the ...
Cached Biology News:First wood-digesting enzyme found in bacteria could boost biofuel production 2New parallelization technique boosts our ability to model biological systems 2Scripps Research scientist wins $1.9 million grant to study malaria 2
Monoclonal 8C2.1 is specific for Bunyavirus G1 as tested by neutralization, immunoprecipitation and immunobinding assays....
...
... stains tumor cells of embryonal carcinoma of testis ... cell tumors like seminoma. Glandular epithelium of yolk ... and endocrine cells of stomach and acini cells ... positive. Epitope: Carbohydrate portion on human ...
Ras-related C3 botulinum toxin substrate 1...
Biology Products: